Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer.

George TJ, Franke AJ, Chakravarthy AB, Das P, Dasari A, El-Rayes BF, Hong TS, Kinsella TJ, Landry JC, Lee JJ, Monjazeb AM, Jacobs SA, Raben D, Rahma OE, Williams TM, Wu C, Coleman CN, Vikram B, Ahmed MM.

Cancer. 2019 Apr 24. doi: 10.1002/cncr.32150. [Epub ahead of print] Review.

PMID:
31017664
2.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C, Boileau JF, Provencher L, Robidoux A, Rimawi M, McIntosh SA, Shalaby I, Stein RC, Thirlwell M, Dolling D, Morden J, Snowdon C, Perry S, Cornman C, Batten LM, Jeffs LK, Dodson A, Martins V, Modi A, Osborne CK, Pogue-Geile KL, Cheang MCU, Wolmark N, Julian TB, Fisher K, MacKenzie M, Wilcox M, Huang Bartlett C, Koehler M, Dowsett M, Bliss JM, Jacobs SA.

J Clin Oncol. 2019 Jan 20;37(3):178-189. doi: 10.1200/JCO.18.01624. Epub 2018 Dec 6.

PMID:
30523750
3.

Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations.

Pal R, Wei N, Song N, Wu S, Kim RS, Wang Y, Gavin PG, Lucas PC, Srinivasan A, Allegra CJ, Jacobs SA, Paik S, Schmitz JC, Pogue-Geile KL.

PLoS One. 2018 Aug 17;13(8):e0200836. doi: 10.1371/journal.pone.0200836. eCollection 2018.

4.

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, Robert NJ, Hopkins JO, O'Shaughnessy JA, Dang CT, Gómez HL, Fehrenbacher L, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Jeong JH, Colangelo LH, Swain SM, Mamounas EP, Jones SE, Wolmark N.

J Clin Oncol. 2017 Aug 10;35(23):2647-2655. doi: 10.1200/JCO.2016.71.4147. Epub 2017 Apr 11.

5.

Conformational flexibility of an anti-IL-13 DARPin†.

Teplyakov A, Malia TJ, Obmolova G, Jacobs SA, O'Neil KT, Gilliland GL.

Protein Eng Des Sel. 2017 Jan;30(1):31-37. Epub 2016 Nov 23.

PMID:
27881684
6.

Engineering a targeted delivery platform using Centyrins.

Goldberg SD, Cardoso RM, Lin T, Spinka-Doms T, Klein D, Jacobs SA, Dudkin V, Gilliland G, O'Neil KT.

Protein Eng Des Sel. 2016 Dec;29(12):563-572. Epub 2016 Oct 13.

PMID:
27737926
7.

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.

Smith JW 2nd, Buyse ME, Rastogi P, Geyer CE Jr, Jacobs SA, Patocskai EJ, Robidoux A, Conlin AK, Ansari B, Keogh GP, Stella PJ, Gross HM, Lord RS, Polikoff JA, Mauquoi C, Mamounas EP, Swain SM, Wolmark N.

Clin Breast Cancer. 2017 Feb;17(1):48-54.e3. doi: 10.1016/j.clbc.2016.07.008. Epub 2016 Jul 28.

PMID:
27693116
8.

Constellation recovery and impairment evaluation through minimization of the blind EVM.

Jacobs SA, Marsland RA.

Opt Express. 2016 Sep 19;24(19):21708-21. doi: 10.1364/OE.24.021708.

PMID:
27661909
9.

Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics.

Jacobs SA, Gibbs AC, Conk M, Yi F, Maguire D, Kane C, O'Neil KT.

Protein Eng Des Sel. 2015 Oct;28(10):385-93. doi: 10.1093/protein/gzv040. Epub 2015 Aug 13.

PMID:
26275855
10.

HER2 activating mutations are targets for colorectal cancer treatment.

Kavuri SM, Jain N, Galimi F, Cottino F, Leto SM, Migliardi G, Searleman AC, Shen W, Monsey J, Trusolino L, Jacobs SA, Bertotti A, Bose R.

Cancer Discov. 2015 Aug;5(8):832-41. doi: 10.1158/2159-8290.CD-14-1211.

11.

Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9.

Abraham J, Robidoux A, Tan AR, Limentani S, Sturtz K, Shalaby I, Alcorn H, Buyse ME, Wolmark N, Jacobs SA.

Breast Cancer Res Treat. 2015 Jul;152(2):399-405. doi: 10.1007/s10549-015-3466-4. Epub 2015 Jul 1.

PMID:
26126970
12.

Induced conformational change in human IL-4 upon binding of a signal-neutralizing DARPin.

Obmolova G, Teplyakov A, Malia TJ, Keough E, Luo J, Sweet R, Jacobs SA, Yi F, Hippensteel R, O'Neil KT, Gilliland GL.

Proteins. 2015 Jun;83(6):1191-7. doi: 10.1002/prot.24815. Epub 2015 May 8.

13.

Contribution of the two genes encoding histone variant h3.3 to viability and fertility in mice.

Tang MC, Jacobs SA, Mattiske DM, Soh YM, Graham AN, Tran A, Lim SL, Hudson DF, Kalitsis P, O'Bryan MK, Wong LH, Mann JR.

PLoS Genet. 2015 Feb 12;11(2):e1004964. doi: 10.1371/journal.pgen.1004964. eCollection 2015 Feb.

14.

Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.

Tan AR, Johannes H, Rastogi P, Jacobs SA, Robidoux A, Flynn PJ, Thirlwell MP, Fehrenbacher L, Stella PJ, Goel R, Julian TB, Provencher L, Bury MJ, Bhatt K, Geyer CE Jr, Swain SM, Mamounas EP, Wolmark N.

Breast Cancer Res Treat. 2015 Jan;149(1):163-9. doi: 10.1007/s10549-014-3221-2. Epub 2014 Dec 27.

PMID:
25542269
15.

Targeting the NMDA receptor subunit NR2B for treating or preventing age-related memory decline.

Wang D, Jacobs SA, Tsien JZ.

Expert Opin Ther Targets. 2014 Oct;18(10):1121-30. doi: 10.1517/14728222.2014.941286. Epub 2014 Aug 24. Review.

PMID:
25152202
16.
17.

Selection of high-affinity Centyrin FN3 domains from a simple library diversified at a combination of strand and loop positions.

Diem MD, Hyun L, Yi F, Hippensteel R, Kuhar E, Lowenstein C, Swift EJ, O'Neil KT, Jacobs SA.

Protein Eng Des Sel. 2014 Oct;27(10):419-29. doi: 10.1093/protein/gzu016. Epub 2014 Apr 30.

PMID:
24786107
18.

N-terminal β-strand swapping in a consensus-derived alternative scaffold driven by stabilizing hydrophobic interactions.

Luo J, Teplyakov A, Obmolova G, Malia TJ, Chan W, Jacobs SA, O'Neil KT, Gilliland GL.

Proteins. 2014 Jul;82(7):1527-33. doi: 10.1002/prot.24517. Epub 2014 Feb 18.

PMID:
24464739
19.

C-terminal β-strand swapping in a consensus-derived fibronectin Type III scaffold.

Teplyakov A, Obmolova G, Malia TJ, Luo J, Jacobs SA, Chan W, Domingo D, Baker A, O'Neil KT, Gilliland GL.

Proteins. 2014 Jul;82(7):1359-69. doi: 10.1002/prot.24502. Epub 2014 Feb 12.

PMID:
24375666
20.

Safety assessment of myogenic stem cell transplantation and resulting tumor formation.

Jacobs SA, Lane FL, Pham QA, Nistor G, Robles R, Chua C, Boubion B, Osann K, Keirstead H.

Female Pelvic Med Reconstr Surg. 2013 Nov-Dec;19(6):362-8. doi: 10.1097/SPV.0000000000000035.

PMID:
24165451
21.

In vivo recovery of the injured anal sphincter after repair and injection of myogenic stem cells: an experimental model.

Lane FL, Jacobs SA, Craig JB, Nistor G, Markle D, Noblett KL, Osann K, Keirstead H.

Dis Colon Rectum. 2013 Nov;56(11):1290-7. doi: 10.1097/DCR.0b013e3182a4adfb.

PMID:
24105005
22.

Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study.

Jankowitz RC, Abraham J, Tan AR, Limentani SA, Tierno MB, Adamson LM, Buyse M, Wolmark N, Jacobs SA.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1205-12.

PMID:
24077916
23.

Randomized prospective crossover study of interstim lead wire placement with curved versus straight stylet.

Jacobs SA, Lane FL, Osann KE, Noblett KL.

Neurourol Urodyn. 2014 Jun;33(5):488-92. doi: 10.1002/nau.22437. Epub 2013 Jun 4.

PMID:
23737158
24.

Mutual interaction between human multipotent adult progenitor cells and NK cells.

Jacobs SA, Plessers J, Pinxteren J, Roobrouck VD, Verfaillie CM, Van Gool SW.

Cell Transplant. 2014;23(9):1099-110. doi: 10.3727/096368913X665585.

PMID:
23562064
25.

Conditional allelic replacement applied to genes encoding the histone variant H3.3 in the mouse.

Tang MC, Jacobs SA, Wong LH, Mann JR.

Genesis. 2013 Feb;51(2):142-6. doi: 10.1002/dvg.22366. Epub 2013 Feb 7.

PMID:
23315948
26.

Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells.

Jacobs SA, Roobrouck VD, Verfaillie CM, Van Gool SW.

Immunol Cell Biol. 2013 Jan;91(1):32-9. doi: 10.1038/icb.2012.64. Review.

27.

Human multipotent adult progenitor cells are nonimmunogenic and exert potent immunomodulatory effects on alloreactive T-cell responses.

Jacobs SA, Pinxteren J, Roobrouck VD, Luyckx A, van't Hof W, Deans R, Verfaillie CM, Waer M, Billiau AD, Van Gool SW.

Cell Transplant. 2013;22(10):1915-28. doi: 10.3727/096368912X657369. Epub 2012 Oct 1.

PMID:
23031260
28.

Image quality improvement using an image-based noise reduction algorithm: initial experience in a phantom model for urinary stones.

Demehri S, Salazar P, Steigner ML, Atev S, Masoud O, Raffy P, Jacobs SA, Rybicki FJ.

J Comput Assist Tomogr. 2012 Sep-Oct;36(5):610-5.

PMID:
22992614
29.

Normal DNA methylation dynamics in DICER1-deficient mouse embryonic stem cells.

Ip J, Canham P, Choo KH, Inaba Y, Jacobs SA, Kalitsis P, Mattiske DM, Ng J, Saffery R, Wong NC, Wong LH, Mann JR.

PLoS Genet. 2012 Sep;8(9):e1002919. doi: 10.1371/journal.pgen.1002919. Epub 2012 Sep 6.

30.

Mechanisms of self-association of a human monoclonal antibody CNTO607.

Bethea D, Wu SJ, Luo J, Hyun L, Lacy ER, Teplyakov A, Jacobs SA, O'Neil KT, Gilliland GL, Feng Y.

Protein Eng Des Sel. 2012 Oct;25(10):531-7. Epub 2012 Aug 22.

PMID:
22915597
31.

genetic overexpression of NR2B subunit enhances social recognition memory for different strains and species.

Jacobs SA, Tsien JZ.

PLoS One. 2012;7(4):e36387. doi: 10.1371/journal.pone.0036387. Epub 2012 Apr 27.

32.

Design of novel FN3 domains with high stability by a consensus sequence approach.

Jacobs SA, Diem MD, Luo J, Teplyakov A, Obmolova G, Malia T, Gilliland GL, O'Neil KT.

Protein Eng Des Sel. 2012 Mar;25(3):107-17. doi: 10.1093/protein/gzr064. Epub 2012 Jan 12.

PMID:
22240293
33.

In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior.

Carvajal-Cuenca A, Sua LF, Silva NM, Pittaluga S, Royo C, Song JY, Sargent RL, Espinet B, Climent F, Jacobs SA, Delabie J, Naresh KN, Bagg A, Brousset P, Warnke RA, Serrano S, Harris NL, Swerdlow SH, Jaffe ES, Campo E.

Haematologica. 2012 Feb;97(2):270-8. doi: 10.3324/haematol.2011.052621. Epub 2011 Nov 4.

34.

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.

Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, Letzer J, Amin B, Williams ME, Smith S, Saleh A, Rosen P, Shi H, Parasuraman S, Cheson BD.

J Clin Oncol. 2011 Sep 1;29(25):3389-95. doi: 10.1200/JCO.2010.32.1844. Epub 2011 Aug 1.

PMID:
21810687
35.

Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.

Rastogi P, Buyse ME, Swain SM, Jacobs SA, Robidoux A, Liepman MK, Pajon ER, Dy PA, Posada JG Jr, Melnik MK, Piette F, Geyer CE Jr, Mamounas EP, Wolmark N.

Clin Breast Cancer. 2011 Aug;11(4):228-34. doi: 10.1016/j.clbc.2011.04.001. Epub 2011 May 4.

PMID:
21684812
36.

Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions.

Roobrouck VD, Clavel C, Jacobs SA, Ulloa-Montoya F, Crippa S, Sohni A, Roberts SJ, Luyten FP, Van Gool SW, Sampaolesi M, Delforge M, Luttun A, Verfaillie CM.

Stem Cells. 2011 May;29(5):871-82. doi: 10.1002/stem.633.

37.

Adrenal insufficiency as presenting feature of non-Hodgkin lymphoma.

Jacobs BL, Blodgett TM, Monaco SE, Hrebinko RL, Jacobs SA.

Can J Urol. 2010 Oct;17(5):5411-4.

PMID:
20974041
38.

Adult consumers' understanding and use of information on food labels: a study among consumers living in the Potchefstroom and Klerksdorp regions, South Africa.

Jacobs SA, de Beer H, Larney M.

Public Health Nutr. 2011 Mar;14(3):510-22. doi: 10.1017/S1368980010002430. Epub 2010 Oct 13.

PMID:
20939940
39.

Structure-based engineering of a monoclonal antibody for improved solubility.

Wu SJ, Luo J, O'Neil KT, Kang J, Lacy ER, Canziani G, Baker A, Huang M, Tang QM, Raju TS, Jacobs SA, Teplyakov A, Gilliland GL, Feng Y.

Protein Eng Des Sel. 2010 Aug;23(8):643-51. doi: 10.1093/protein/gzq037. Epub 2010 Jun 11.

PMID:
20543007
40.

Detection of a mammographically occult invasive lobular breast carcinoma by PET/CT in a patient with lymphoma.

Setlik DE, Joyce JM, Jacobs SA.

Clin Nucl Med. 2009 Dec;34(12):939-40. doi: 10.1097/RLU.0b013e3181becde7. No abstract available.

PMID:
20139842
41.

Cross-interaction chromatography: a rapid method to identify highly soluble monoclonal antibody candidates.

Jacobs SA, Wu SJ, Feng Y, Bethea D, O'Neil KT.

Pharm Res. 2010 Jan;27(1):65-71. doi: 10.1007/s11095-009-0007-z. Epub 2009 Nov 13.

PMID:
19911257
42.

Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma.

Jacobs SA, Swerdlow SH, Kant J, Foon KA, Jankowitz R, Land SR, DeMonaco N, Joyce J, Osborn JL, Evans TL, Schaefer PM, Luong TM.

Clin Cancer Res. 2008 Nov 1;14(21):7088-94. doi: 10.1158/1078-0432.CCR-08-0529.

43.

Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin's lymphoma.

Jacobs SA, Harrison AM, Swerdlow SH, Foon KA, Avril N, Vidnovic N, Joyce J, DeMonaco N, McCarty KS Jr.

Mol Imaging Biol. 2009 Jan-Feb;11(1):39-45. doi: 10.1007/s11307-008-0170-3. Epub 2008 Sep 5.

PMID:
18773247
44.

Specificity of the chromodomain Y chromosome family of chromodomains for lysine-methylated ARK(S/T) motifs.

Fischle W, Franz H, Jacobs SA, Allis CD, Khorasanizadeh S.

J Biol Chem. 2008 Jul 11;283(28):19626-35. doi: 10.1074/jbc.M802655200. Epub 2008 May 1.

45.

Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-hodgkin lymphoma.

Jankowitz R, Joyce J, Jacobs SA.

Clin Nucl Med. 2008 Feb;33(2):94-6. doi: 10.1097/RLU.0b013e31815ef825.

PMID:
18209526
46.
47.

The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas.

Jacobs SA, Foon KA.

Expert Opin Biol Ther. 2007 Nov;7(11):1749-62. Review.

PMID:
17961097
49.

A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.

Dennison SK, Jacobs SA, Wilson JW, Seeger J, Cescon TP, Raymond JM, Geyer CE, Wolmark N, Swain SM.

Invest New Drugs. 2007 Dec;25(6):545-51. Epub 2007 Jun 12.

PMID:
17563856
50.

Focal radiation fibrosis after radioimmunotherapy for follicular non-Hodgkin lymphoma.

DeMonaco NA, McCarty KS Jr, Joyce J, Jacobs SA.

Clin Lymphoma Myeloma. 2007 Mar;7(5):369-72.

PMID:
17562248

Supplemental Content

Loading ...
Support Center